Round Table

Safety and efficacy of gene transfer by electroporation: localized and controlled delivery can elevate gene therapy

A Round Table event

An industry-academia-regulators (EMA&FDA) EBTT2024 round table on cell-based therapies and gene transfer by electroporation – time to capitalize on human genome project? The aim of the round table is to bring together industry, regulators and academia to identify gaps in knowledge for developing and optimizing medical treatments.

Webinar: live online and on-site
15:15-17:30 (CET), November 14, 2024 | University of Ljubljana – Ljubljana, Slovenia
Round Table event: “Safety and efficacy of gene transfer by electroporation: localized and controlled delivery can elevate gene therapy”

Register now

Please note: Attendance is free and open to anyone interested, however, registration for both online or on-site participation is mandatory. On-site presence is limited due to limited space available.


Program and panelists

  1. David Sourdive – Cellectis, USA: Gene editing for cell-based therapies
  2. Maja Čemažar – Ljubljana Institute of Oncology, Slovenia: pDNA number of copies expressed
  3. Marek M. Drozdz – RenBio, USA: Muscle-produced therapeutics vs therapeutic range
  4. Richard Heller – USF, USA: mRNA vs pDNA
  5. Jeffrey Skolnik and Paul Fisher – Inovio, USA: INO-3107: DNA Therapy for RRP, a Rare Respiratory Disease
  6. Marie-Pierre Rols – CNRS, France: Intracellular transport – how pDNA escapes from endosomes
  7. Paulo Garcia – Kytopen, USA: Genome engineering
  8. Loree Heller – USF, USA: Immunogenicity/DNA sensors
  9. Damijan Miklavčič – University of Ljubljana, Slovenia: Different pulse parameters/protocols for different payloads and different cells?